The EEF1AKMT3/MAP2K7/TP53 axis suppresses tumor invasiveness and metastasis in gastric cancer. (28th September 2022)

• Record Type: Journal Article
• Authors: Hong, Yo Han; Aziz, Nur; Park, Jae Gwang; Lee, Dagyeong; Kim, Jin Kyeong; Kim, Seung A.; Choi, Wooram; Lee, Chae Young; Lee, Hwa Pyoung; Huyen Trang, Ha Thi; Kim, Han Gyung; Jeon, Young-Jun; Kim, Bokyoung; Kim, Younghoon; Kim, Kyung-Hee; Yoo, Byong Chul; Han, Jeung-Whan; Parameswaran, Narayana; Kim, Ji Hye; Hur, Hoon; Cho, Jae Youl
• Is Part Of: Cancer letters. Volume 544(2022)
• Publication Date: 2022-09-28
• Subjects: EEF1AKMT3 -- MAP2K7 -- Protein methylation -- TP53 -- Gastric tumor -- Tumor suppressor; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.215803
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: The importance of methylation in the tumorigenic responses of nonhistone proteins, such as TP53, PTEN, RB1, AKT, and STAT3, has been emphasized in numerous studies. In parallel, the corresponding nonhistone protein methyltransferases have been acknowledged in the pathophysiology of cancer. Thus, this study aimed to explore the pathological role of a nonhistone methyltransferase in gastric cancer (GC), identify nonhistone substrate protein, and understand the underlying mechanism. Interestingly, among the 24 methyltransferases and methyltransferase family 16 (MTF16) proteins, EEF1AKMT3 (METTL21B) expression was prominently lower in GC tissues than in normal adjacent tissues and was associated with a worse prognosis. In addition, EEF1AKMT3-knockdown induced gastric tumor invasiveness and migration. Through gain and loss-of-function studies, mass spectrometry analysis, RNA-seq, and phospho-antibody array, we identified EEF1AKMT3 as a novel tumor-suppressive methyltransferase that catalyzes the monomethylation of MAP2K7 (MKK7) at K296, thereby decreasing the phosphorylation, ubiquitination, and degradation of TP53. Furthermore, EEF1AKMT3, p-MAP2K7, and TP53 protein levels were positively correlated in GC tissues. Collectively, our results delineate the tumor-suppressive function of the EEF1AKMT3/MAP2K7/TP53 signaling axis and suggest the dysregulation of the signaling axis as potential targeted therapy in GC. Highlights: EEF1AKMT3 was identified as gastric tumor suppressor using in vitro and in vivo model. As a novel EEF1AKMT3 substrate, MAP2K7 was found to be methylated at K296. Methylated MAP2K7 was revealed to promote TP53 protein stability, . Experimental data showed that a molecular complex composed of EEF1AKMT3, MAP2K7, and TP53 acts as a tumor suppressor axis and highlights therapeutic exploitability in gastric cancer.